Returned to Category 1 compounding status in February 2026 Published literature: Extensive veterinary medicine literature plus preclinical studies on muscle, tendon, and cardiac tissue For the regulatory timeline including the February 2026 reclassification and current compounding eligibility see our TB-500 FDA approval status 2026 breakdown
This allows for the peptides to stay in solution with minimal degradation, allowing them to remain active within the given solution over extended periods of time
The barrier failure comes first: When barrier proteins like filaggrin break down or are genetically underproduced, the skin loses its ability to retain moisture and block environmental triggers
Cost, Access, and Practical Considerations Current Market Status As investigational compounds, cagrilintide and retatrutide are not yet available through standard pharmaceutical channels
Keeping a symptom diary during the first 4 to 8 weeks helps separate these overlapping symptom sources
So a reconstituted vial is not germ-proof
